Stephen D Dertinger
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2015First federal award
$8.4MFederal grants as PI17 awards
8Patents grantedLatest Nov 28, 2023
203Papers6,326 citations
Federal awards and patents by year
AwardsPatents
17 awards · $8.4M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Aug 10, 2026 | NIH | SBIR Phase II Modeling the Responsiveness of Sensitive Populations to Genotoxic Agents Using DNA Repair Inhibitors | $844K | Litron Laboratories Ltd |
| Sep 5, 2025 | NIH | SBIR Phase II Modeling the Responsiveness of Sensitive Populations to Genotoxic Agents Using DNA Repair Inhibitors | $824K | Litron Laboratories Ltd |
| Jul 14, 2023 | NIH | SBIR Phase I Modeling the Responsiveness of Sensitive Populations to Genotoxic Agents Using DNA Repair Inhibitors | $230K | Litron Laboratories Ltd |
| Mar 8, 2023 | NIH | SBIR Phase II High Throughput Screen and High Information Follow-Up Tests for Genotoxicants | $683K | Litron Laboratories Ltd |
| Apr 7, 2022 | NIH | SBIR Phase II High Throughput Screen and High Information Follow-Up Tests for Genotoxicants | $945K | Litron Laboratories Ltd |
| Apr 2, 2021 | NIH | SBIR Phase II High Throughput Screen and High Information Follow-Up Tests for Genotoxicants | $205K | Litron Laboratories Ltd |
| Jan 3, 2020 | NIH | SBIR Phase II Next Generation Testing Strategies for Assessment of Genotoxicity | $475K | Litron Laboratories Ltd |
| Aug 26, 2019 | NIH | SBIR Phase II Validation of Cross-Species Biomarkers of DNA Damage | $617K | Litron Laboratories Ltd |
| Dec 13, 2018 | NIH | SBIR Phase II Next Generation Testing Strategies for Assessment of Genotoxicity | $482K | Litron Laboratories Ltd |
| Aug 23, 2018 | NIH | SBIR Phase II Validation of Cross-Species Biomarkers of DNA Damage | $629K | Litron Laboratories Ltd |
| Feb 9, 2018 | NIH | SBIR Phase II Next Generation Testing Strategies for Assessment of Genotoxicity | $179K | Litron Laboratories Ltd |
| Jan 8, 2018 | NIH | SBIR Phase II Validation of Cross-Species Biomarkers of DNA Damage | $173K | Litron Laboratories Ltd |
| Dec 1, 2017 | NIH | SBIR Phase II Automation of a Liver Genotoxicity Assay | $510K | Litron Laboratories Ltd |
| Nov 30, 2016 | NIH | SBIR Phase II Automation of a Liver Genotoxicity Assay | $450K | Litron Laboratories Ltd |
| Feb 11, 2016 | NIH | SBIR Phase II Automation of a Liver Genotoxicity Assay | $173K | Litron Laboratories Ltd |
| Jan 29, 2016 | NIH | SBIR Phase II Biomarker Matrix for Genotoxicity Mode of Action | $484K | Litron Laboratories Ltd |
| Feb 1, 2015 | NIH | SBIR Phase II Biomarker Matrix for Genotoxicity Mode of Action | $493K | Litron Laboratories Ltd |
9 patents as inventor
- US 10000793Litron Laboratories LtdJun 19, 2018
- US 10802013Litron Laboratories LtdOct 13, 2020
- US 11016101Litron Laboratories LtdMay 25, 2021
- US 11828763Litron Laboratories LtdNov 28, 2023
- US 8889369Litron Laboratories LtdNov 18, 2014
- US 9285365Litron Laboratories LtdMar 15, 2016
- US 9470694Litron Laboratories LtdOct 18, 2016
- US 9857358Litron Laboratories LtdJan 2, 2018
- US Litron Laboratories Ltd—
Matched by the first inventor’s name and the patent’s company.
Peer ranks
Federal funding#97
Awards as PI#29
Patents#6
Companies
- Litron Laboratories LtdLinked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.